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MEDICAL CARE COSTS OF PRIMARY OPEN-ANGLE
GLAUCOMA IN THE UNITED STATES:A NATIONAL ESTIMATE
USING THE MEDICAL EXPENDITURE PANEL SURVEY
Mychaskiw MA1, Schwartz GF2
1Pﬁzer, Inc, New York, NY, USA; 2Greater Baltimore Medical Center,
Baltimore, MD, USA
OBJECTIVES: The objective of this study was to estimate the
direct costs of medical care associated with the treatment of
primary open-angle glaucoma (POAG) in the United States.
METHODS: Retrospective analysis was conducted of the 2001
Medical Expenditure Panel Survey (MEPS) data. The MEPS col-
lected survey and administrative claims data from a nationally
representative sample of 33,556 respondents and from respon-
dents’ health care and insurance providers. Data extracted for
this study included demographics (patients >40 years of age),
medical conditions, and utilization of and payments for medical
care. Patients with POAG were identiﬁed using ICD-9-CM codes
and direct costs were calculated using patient and third-party
payments for POAG-related medical events by type of care 
provided (ofﬁce-based provider visits, prescription medications,
and outpatient services). Sample estimates were weighted and
projected to the population and 95% conﬁdence limits were 
calculated using the Taylor expansion method. RESULTS: The
estimated prevalence of POAG using the MEPS was 1.25%
(95% C.L. = 0.94%–1.56%) or 1,640,087 individuals. Total
direct costs of POAG were $1,788,914,417, with an average cost
of $1,091 per patient. Prescription medications accounted for
$1,042,509,011 (mean cost / prescription = $58; 95% C.L. =
$54–$63) of direct costs. Ofﬁce-based provider visits represented
$619,401,436 (mean cost / visit = $105; 95% C.L. = $96–$113)
and outpatient services represented $127,003,970 (mean cost /
patient = $316; 95% C.L. = $198–$434). CONCLUSIONS:
Using the MEPS, POAG was estimated to affect nearly 1.7
million individuals with resultant medical care costs approach-
ing $2 billion. Although prescription medications accounted for
58% of total direct costs, they had the lowest mean cost across
the types of care. It may well be that innovative drug therapies,
which are preferable to less effective alternatives, contribute to
less utilization of more costly medical care.
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COST OF GLAUCOMA TO THE CALIFORNIA MEDICAID
(MEDI-CAL) PROGRAM BETWEEN 1995 AND 2002
Lee LJ1,Yu AP1,Yu YF2, Nichol MB1
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OBJECTIVES: To estimate the treatment costs of glaucoma to
the California Medicaid program from 1995–2002. METHODS:
Patients with glaucoma (ICD-9 = 365.xx) were identiﬁed using
a 20% sample of the Medi-Cal administrative claims database
from January 1, 1995 to December 31, 2002. Yearly cost was
compared between glaucoma patients and controls through a
case-control match. For each patient with glaucoma, three 
Medi-Cal enrollees without glaucoma were matched based on
age and gender. In addition, expenditures were calculated for
inpatient, outpatient, pharmacy, and other medical costs during
the ﬁrst year after the initial glaucoma diagnosis. All costs were
eligibility-adjusted by the number of eligible months. RESULTS:
In total, 32,395 glaucoma patients matched a cohort of 97,185
controls. The average age was 65.5 years and 65% were female.
The average yearly costs for glaucoma patients were $4191 and
$4021 for control patients. The cost steadily increased over the
eight-year study period at a rate higher in glaucoma patients than
in the control group. For the glaucoma patients, the treatment
costs in 2002 were more than twice of controls in 1995 ($5974
vs. $2597), without adjusting for inﬂation. On average, the ﬁrst
year treatment costs after the initial diagnosis for glaucoma
patients were $4347, where $1554 (35.7%) were pharmacy
costs, $1315 (30.2%) hospitalization, $595 outpatient, and
other medical costs were $1086. Additional analysis suggested
that in year 2002, Medi-Cal incurred an incremental $116
million dollars due to glaucoma. CONCLUSIONS: The eco-
nomic burden of glaucoma to the Medi-Cal program doubled
between 1995 and 2002.
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PATIENT-REPORTED VISUAL FUNCTION IN LOW-VISION
POPULATIONS (NEI-VFQ):AN ANALYSIS WITH
COMPARISONS OF READING PERFORMANCE, CONTRAST
SENSITIVITY, SCOTOMA TESTING,AND VISUAL ACUITY
Tencer T1, Chang TS1, Fletcher DC2, Globe DR1
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2Smith-Kettlewell Eye Research Institute, San Francisco, CA, USA
OBJECTIVES: To assess the criterion validity of a patient
reported visual function instrument (NEI-VFQ) in a cohort of
low vision patients using clinical parameters. METHODS: A
subset of the NEI-VFQ-51 items was administered to 255 low
vision patients. Contrast sensitivity (CS), visual acuity (VA),
reading acuity (RA), critical print size and maximum reading rate
were measured. Retinal visual function was evaluated and foveal
functioning assessed. The association of the NEI-VFQ subscales
with clinical parameters were assessed by Pearson’s correlation
coefﬁcients. Subscale scores between patients with stable/
unstable vision loss and a functioning/non-functioning fovea
were compared using Students T-test. Linear regression models
were used to calculate the differences in scores that corresponded
to a clinically signiﬁcant three-line loss in visual acuity.
RESULTS: Binocular VA was signiﬁcantly correlated with the
near vision (r = -0.56, p < 0.0001) and distance vision subscales
(r = -0.45, p < 0.0001). Contrast sensitivity was moderately cor-
related with near vision (r = 0.36, p < 0.001) and more strongly
correlated with distance vision (r = 0.42, p < 0.001). The
maximum reading rate was signiﬁcantly correlated with VA (r =
0.53, p < 0.0001). Patients with unstable visual loss reported a
signiﬁcantly lower mean composite score (6.0 points, p = 0.03),
expectation score (19.9 points, p < 0.0001) and social function-
ing score (7.9 points, p = 0.03) than patients with stable visual
loss. Signiﬁcant differences were found in the near (22.5 points,
p < 0.0001), distance (11.8 points, p = 0.015), social function-
ing (15.5 points, p = 0.015), and role limitations (17.0 points, p
= 0.009) subscales between patients with a functioning versus
non-functioning fovea. A three-line difference in visual acuity
was associated with a 5.8 to 10.9 point difference in the NEI-
VFQ domains. CONCLUSION: The NEI-VFQ correlated sig-
niﬁcantly with reading speed and binocular visual acuity. Foveal
functioning is signiﬁcantly associated with the near and distance
subscales, as well as reading speeds. A minimally important clin-
ical difference of three lines of VA is associated with a 5.8–10.9
difference in NEI-VFQ scores.
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OBJECTIVES: The purpose of this project was to assess the
prevalence and risk factors for diarrhea at a large tertiary care
medical center. METHODS: Prospective cross-sectional study
conducted on December 13, 2004 in a 600-bed tertiary care
medical center. All patients hospitalized for greater than 24-
hours on the study day were interviewed. Patients were asked if
they were experiencing diarrhea (deﬁned as passing of two or
more unformed stools in the past 24-hours.) All patients report-
ing diarrhea were tested for Clostridium difﬁcile. Patient demo-
graphics, and use of antibiotics, tube feeds, GI motility agents,
steroids, chemotherapy proton pump inhibitors were collected
for every patient. Chi-square analysis was used to determine risk
factors for diarrhea. RESULTS: A total of 485 patients were
interviewed for the study, of which 60 (12.3%) patients reported
diarrhea. The risk factors for diarrhea include Clostridium difﬁ-
cile infection (OR 15.1, p < 0.0001), hospitalization duration 
(p < 0.0001), current use of antibiotics (OR 1.95, p < 0.0166),
and tube feeds (OR 3.34, p < 0.0018). Prevalence of diarrhea
increased with longer duration of hospitalization (p = 0.03).
CONCLUSION: Twelve percent of hospitalized patients experi-
enced diarrhea in our study. Common risk factors for diarrhea
included C. difﬁcile infection, current use of antibiotics, tube
feeds, or longer hospitalizations.
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OBJECTIVE: To develop a budget impact model that assesses
the economic impact of adding tegaserod for the management of
irritable bowel syndrome with constipation to a managed care
organization’s (MCO) formulary. METHODS: The model esti-
mates per patient and per-member per-month (PMPM) economic
impact of two patient subgroups six-months prior to and six-
months after the initiation of tegaserod. The incremental budget
impact of tegaserod was then calculated by subtracting the prior
period costs from the post period costs. The two patient sub-
groups were 1) females with an IBS diagnosis (FIBS); and 2)
males and females with other GI diagnosis (GID). Resource uti-
lization data were based on a retrospective, longitudinal study
of 3365 tegaserod users from a large, geographically-diverse
MCO utilizing medical and pharmacy administrative claims
data. We used prevalence and tegaserod treatment rates observed
from the aforementioned MCO. Sensitivity analyses were per-
formed by varying several model inputs parameters. RESULTS:
The base-case model resulted in an incremental PMPM budget
impact associated with the use of tegaserod of $0.01. Total 
per-patient budget impact (for all resources, including tegaserod)
for a six-month period was $274.34 for FIBS and $301.84 
for GID. Overall, 25.9% (29.0% for FIBS and 21.9% for GID)
of the cost of tegaserod was offset by decreases in resource uti-
lization. Key drivers of post-tegaserod reductions in resource
costs were hospital stays, abdominal and pelvic CAT scans,
colonoscopies (for FIBS), and outpatient ofﬁce consultations and
emergency room visits (for GID). CONCLUSIONS: Tegaserod
therapy can decrease GI-related resource use, resulting in a sig-
niﬁcant cost-offset percentage. When the associated budget
impact of adding tegaserod to formulary is absorbed across 
an entire MCO population, the PMPM impact of tegaserod is
small.
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THE ECONOMIC IMPLICATIONS OF SOMATROPIN [RDNA
ORIGIN] MANAGEMENT IN PATIENTS WITH SHORT 
BOWEL SYNDROME
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OBJECTIVES: Short bowel syndrome (SBS) results from exten-
sive surgical removal of portions of the small intestine, and leads
to serious morbidity and shortened life expectancy. A recent trial
showed that use of somatropin [rDNA origin] for injection
(rhGH) signiﬁcantly reduces the need for standard treatments
such as parenteral nutrition (PN), which signiﬁcantly impair
quality of life. This study sought to evaluate the economic impact
of this new treatment. METHODS: A discrete event simula-
tion was developed to compare a regimen of daily rhGH for 
four weeks with PN alone in the management of patients with
SBS. Risks of treatment- and disease-related complications and
resource use were modeled in two identical cohorts of 1000
patients for two years. Rates of disease-related events (e.g.,
biliary problems), including age-dependent mortality, were
assumed to be the same across strategies. Risk functions for each
strategy were estimated from the literature and one randomized
clinical trial. Direct medical costs were obtained from Medicaid
and the literature. Sensitivity analyses were conducted on key
parameters. Direct medical costs are reported in US$2004. All
outcomes were discounted at 3%/yr. RESULTS: Overall, 96.0%
of patients receiving rhGH reduced or eliminated PN use within
six weeks of initiating the regimen; one-third weaned completely;
and PN use decreased 2.8 days. PN was estimated to cost
$118,099 in year one and $132,935 in year two, totaling
$251,033 vs rhGH cost of $84,309, including $17,459 for treat-
ment, in year one, a savings of $33,790 per patient; over two
years $165,559, for a total savings of $85,474. Cost neutrality
is achieved within eight months. Sensitivity analyses showed no
signiﬁcant change in results. CONCLUSIONS: The reduction of
PN use or complete weaning in the vast majority of patients with
rhGH results in a substantial savings and improvement in quality
of life—a dominant strategy.
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Although hepatitis A and B vaccinations are recommended for
patients with chronic hepatitis C virus (HCV), the ideal vacci-
nation strategy is not determined. OBJECTIVE: To model the
cost-effectiveness of two strategies of vaccinating patients with
HCV infection against hepatitis A (HAV) and hepatitis B (HBV)
viruses. The strategies evaluated were: universal vaccination with
the combined HAV and HBV vaccine, and selective vaccination
based on immunity by blood testing. METHODS: A decision
tree computer model was constructed to compare the cost-
effectiveness of the two vaccination strategies from the New
Mexico Veterans Affairs Health Care System (NMHAHCS) per-
spective. A retrospective review of all HCV patients (2542 sub-
jects) at the NMVAHCS was performed to extract prevalence of
immunity to HAV and HBV, and prevalence of decompensated
